ORIC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.366

-28.14%

-0.376

-10.42%

-0.393

-16.49%

Estimates Revision

Stock Price

Go Down

-35.30%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 19.13 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

15.00

Averages

19.13

High

25.00

Current: 0.000

Low

15.00

Averages

19.13

High

25.00

Piper Sandler

Kelsey Goodwin

Overweight

initiated

$22

2026-01-07

New

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$22

2026-01-07

New

initiated

Overweight

Reason

Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals with an Overweight rating and $22 price target. The company's ORIC-944 is a potential best-in-class PRC2 inhibitor capable of becoming a standard of care treatment class in prostate cancer, the analyst tells investors in a research note. Piper believes the ORIC-944 clinical update in Q1 "is likely to represent a value creation event."

Wells Fargo

Overweight

upgrade

$19 -> $25

2025-12-08

Reason

Wells Fargo

Price Target

$19 -> $25

2025-12-08

upgrade

Overweight

Reason

Wells Fargo raised the firm's price target on Oric Pharmaceuticals to $25 from $19 and keeps an Overweight rating on the shares. While enozertinib has largely taken a back seat to ORIC-944, its data presented at ESMO Asia is intriguing and Wells thinks enough for investors to start assigning more credit. The firm believes shares should trade up.

Goldman Sachs

initiated

2025-12-04

Reason

Goldman Sachs

Price Target

2025-12-04

initiated

Reason

Goldman Sachs initiated coverage of Oric Pharmaceuticals with an Early Stage Biotech rating. Oric is a clinical stage biotechnology company with a pipeline of oncology candidates focused on addressing resistance in cancer, the analyst tells investors in a research note.

Evercore ISI

Cory Kasimov

Outperform

initiated

$25

2025-11-20

Reason

Evercore ISI

Cory Kasimov

Price Target

$25

2025-11-20

initiated

Outperform

Reason

Evercore ISI analyst Cory Kasimov initiated coverage of Oric Pharmaceuticals with an Outperform rating and $25 price target. The firm sees a "compelling" opportunity for the company in the "large" prostate cancer market. Oric's lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings, the analyst tells investors in a research note.

JPMorgan

Anupam Rama

maintain

$17 -> $20

2025-11-18

Reason

JPMorgan

Anupam Rama

Price Target

$17 -> $20

2025-11-18

maintain

Reason

JPMorgan analyst Anupam Rama raised the firm's price target on Oric Pharmaceuticals to $20 from $17 and keeps an Overweight rating on the shares. The firm adjusted models in the smid-cap biotech space.

Wolfe Research

Kalpit Patel

Peer Perform

initiated

2025-11-17

Reason

Wolfe Research

Kalpit Patel

Price Target

2025-11-17

initiated

Peer Perform

Reason

Wolfe Research analyst Kalpit Patel initiated coverage of Oric Pharmaceuticals with a Peer Perform rating and no price target. The firm highlights the baseline imbalance in Pfizer's (PFE) mevro study and thinks that the magnitude of benefit may be overstated with the PRC2 inhibitor drug class.

Valuation Metrics

The current forward P/E ratio for Oric Pharmaceuticals Inc (ORIC.O) is -5.30, compared to its 5-year average forward P/E of -5.22. For a more detailed relative valuation and DCF analysis to assess Oric Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.22

Current PE

-5.30

Overvalued PE

-2.01

Undervalued PE

-8.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.87

Current EV/EBITDA

-3.26

Overvalued EV/EBITDA

0.29

Undervalued EV/EBITDA

-6.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 496.64% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ORIC News & Events

Events Timeline

No data

News

1.0

01-06Globenewswire

ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference

4.0

2025-12-16Yahoo Finance

ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation

9.0

2025-12-06Globenewswire

ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients

People Also Watch

Frequently Asked Questions

What is Oric Pharmaceuticals Inc (ORIC) stock price today?

The current price of ORIC is 9.11 USD — it has increased 7.81 % in the last trading day.

What is Oric Pharmaceuticals Inc (ORIC)'s business?

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

What is the price predicton of ORIC Stock?

What is Oric Pharmaceuticals Inc (ORIC)'s revenue for the last quarter?

Oric Pharmaceuticals Inc revenue for the last quarter amounts to -36.67M USD, decreased -4.30 % YoY.

What is Oric Pharmaceuticals Inc (ORIC)'s earnings per share (EPS) for the last quarter?

Oric Pharmaceuticals Inc. EPS for the last quarter amounts to -25147000.00 USD, decreased -13.92 % YoY.

What changes have occurred in the market's expectations for Oric Pharmaceuticals Inc (ORIC)'s fundamentals?

The market is revising No Change the revenue expectations for ORIC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -35.30%.

How many employees does Oric Pharmaceuticals Inc (ORIC). have?

Oric Pharmaceuticals Inc (ORIC) has 115 emplpoyees as of January 09 2026.

What is Oric Pharmaceuticals Inc (ORIC) market cap?

Today ORIC has the market capitalization of 822.94M USD.